Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 10/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3924071 | 0.87 | PARP14 (0.50) | KIF11JAK2TP53MAPTHTT | |
| SCHEMBL6601301 | 0.85 | PARP14 (0.51) | KIF11JAK2TP53MAPTHTT | |
| SCHEMBL11584101 | 0.84 | EGFR (0.46) | KIF11JAK2TP53MAPTHTT | |
| SCHEMBL27500727 | 0.84 | PARP14 (0.49) | KIF11JAK2TP53MAPTHTT | |
| SCHEMBL15560416 | 0.83 | KIF11 (0.47) | KIF11JAK2TP53MAPTHTT | |
| SCHEMBL2429422 | 0.82 | PARP14 (0.51) | KIF11JAK2TP53MAPTHTT | |
| SCHEMBL4786156 | 0.81 | SLC22A6 (0.55) | KIF11JAK2TP53MAPTHTT | |
| SCHEMBL9397133 | 0.80 | POLM (0.50) | PARP14ERAP1 | |
| SCHEMBL27864646 | 0.80 | POLM (0.50) | PARP14ERAP1 | |
| SCHEMBL9398516 | 0.80 | POLM (0.50) | PARP14ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116806157-A | Linker-payload and conjugates thereof | 芬兰吉利科斯有限公司 | 2023-09-26 | — | — | CN | claimed |
| CN-114616250-B | CD8 binding agents and uses thereof | 豪夫迈·罗氏有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118344370-A | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118206655-A | Enhanced chimeric antigen receptor and uses thereof | 得克萨斯大学体系董事会 | 2024-06-18 | — | — | CN | disclosed |
| CN-114901277-B | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-114907271-B | Compositions of benzamide and active compounds and methods of use thereof | 转化药物开发有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117999093-A | Engineered compositions for bone targeted therapy | 威廉马歇莱思大学 | 2024-05-07 | — | — | CN | disclosed |
| CN-117916265-A | OSMR-specific monoclonal antibodies and methods of use thereof | 德克萨斯大学系统董事会 | 2024-04-19 | — | — | CN | disclosed |
| CN-117599061-A | Compounds having anti-tumor activity against cancer cells harboring EGFR or HER2 exon 20 mutations | 得克萨斯州大学系统董事会 | 2024-02-27 | — | — | CN | disclosed |
| CN-110291104-B | Compounds having anti-tumor activity against cancer cells harboring EGFR or HER2 exon 20 mutations | 得克萨斯州大学系统董事会 | 2023-11-03 | — | — | CN | disclosed |
| CN-116917278-A | Divalent fibroblast activation protein ligands for targeted delivery applications | 菲罗化学股份公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116888112-A | Lactams as CBL-B inhibitors | 基因泰克公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116848106-A | Amides as CBL-B inhibitors | 基因泰克公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116806157-A | Linker-payload and conjugates thereof | 芬兰吉利科斯有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-116783180-A | Tricyclic ligands for degradation of IKZF2 or IKZF4 | C4医药公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116782941-A | Combination therapy of Senicague virus for the treatment of checkpoint inhibitor refractory cancers | 塞内卡治疗公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116761883-A | Compositions and methods for the oncolytic treatment of armed Senicaviruses | 塞内卡治疗公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-110831622-B | FGL2 monoclonal antibody and application thereof in treatment of malignant tumors | 德克萨斯大学系统董事会 | 2023-06-20 | — | — | CN | disclosed |
| CN-116113406-A | GAS41 inhibitors and methods of use thereof | 密歇根大学董事会 | 2023-05-12 | — | — | CN | disclosed |